Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 5, 2014, Pages 920-925

  Huang, Kaijun ^a   Zhou, Qian ^b   Wang, Rong ^a   Cheng, Donghui ^a   Ma, Yi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Doxorubicin eluting bead; Hepatocellular carcinoma; Objective tumor response; Survival

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ABDOMINAL PAIN; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHOLECYSTITIS; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DRUG ELUTING BEAD; FATIGUE; FEVER; HUMAN; IMPLANT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; BIBLIOGRAPHIC DATABASE; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; LIVER NEOPLASMS; MORTALITY;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DATABASES, BIBLIOGRAPHIC; DOXORUBICIN; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; SURVIVAL RATE;

EID: 84898885484     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12439     Document Type: Article

References (40)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 2009; 27: 1485-1491.
2. Bolondi L, Sofia S, Siringo S etal. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 2001; 48: 251-259.
3. Sangiovanni A, Del Ninno E, Fasani P etal. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
5. Witczak-Malinowska K, Zadrozny D, Studniarek M etal. Preliminary assessment of utility of radiofrequency ablation technique in treatment of primary hepatocellular carcinoma (HCC) in patients with hepatic cirrhosis. Med. Sci. Monit. 2003; 9: 68-72.
6. Llovet JM, Real MI, Montana X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-1739.
7. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 2003; 37: 429-442.
9. Raoul JL, Heresbach D, Bretagne JF etal. Chemoembolisation of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992; 70: 585-590.
10. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
11. Marelli L, Stigliano R, Triantos C etal. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 2007; 30: 6-25.
12. Spahr L, Becker C, Pugin J, Majno PE, Hadengue A. Acute portal hemodynamics and cytokine changes following selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma. Med. Sci. Monit. 2003; 9: CR383-388.
13. Lewis AL, Gonzalez MV, Lloyd AW etal. DC Bead: in vitro characterisation of a drug-delivery device for transarterial chemoembolisation. J. Vasc. Interv. Radiol. 2006; 17: 335-342.
14. Lewis AL, Gonzalez MV, Leppard SW etal. Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution. J. Mater. Sci. Mater. Med. 2007; 18: 1691-1699.
15. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolisation. J. Vasc. Interv. Radiol. 2006; 17: 1335-1343.
16. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res. 2006; 12: 2563-2567.
17. Varela M, Real MI, Burrel M etal. Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 2007; 46: 474-481.
18. Poon RT, Tso WK, Pang RW etal. A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol. 2007; 5: 1100-1108.
19. Kettenbach J, Stadler A, Katzler IV etal. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc. Intervent. Radiol. 2008; 31: 468-476.
20. Malagari K, Chatzimichael K, Alexopoulou E etal. Transarterial chemoembolisation of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc. Intervent. Radiol. 2008; 31: 269-280.
21. Wells GA, Shea B, O'Connell D etal. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Cited 10 Feb 2013. Available from URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
22. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
23. Song MJ, Park CH, Kim JD etal. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur. J. Gastroenterol. Hepatol. 2011; 23: 521-527.
24. Song MJ, Chun HJ, Song DS etal. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J. Hepatol. 2012; 57: 1244-1250.
25. Recchia F, Passalacqua G, Filauri P etal. Chemoembolization of unresectable hepatocellular carcinoma: decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol. Oncol. Rep. 2012; 27: 1377-1383.
26. Sacco R, Bargellini I, Bertini M etal. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2011; 22: 1545-1552.
27. Ferrer PM, la Parra C, Esteban E etal. Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Radiologia 2011; 53: 246-253.
28. Wiggermann P, Sieron D, Brosche C etal. Transarterial chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med. Sci. Monit. 2011; 17: R189-195.
29. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J. Surg. Oncol. 2010; 101: 476-480.
30. Vogl TJ, Lammer J, Lencioni R etal. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am. J. Roentgenol. 2011; 197: W562-570.
31. Lammer J, Malagari K, Vogl T etal. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 2010; 33: 41-52.
32. Lencioni R, Malagari K, Vogl T. Reduced liver toxicity in intermediate-stage hepatocellular carcinoma patients treated by chemoembolization with drug eluting beads: results from the PRECISION V randomized trial. Hepatology 2009; 50: 1079A.
33. van Malenstein H, Maleux G, Vandecaveye V etal. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-376.
34. Sousa PF, Preto AS, Leão D etal. Transcatheter arterial chemoembolization with doxorubicin eluting beads in the treatment of hepatocellular carcinoma. Acta Med. Port. 2011; 24: 29-36.
35. Namur J, Citron SJ, Sellers MT etal. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J. Hepatol. 2011; 55: 1332-1338.
36. Malbranche C, Boulin M, Guiu B etal. Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma. Bull. Cancer 2011; 98: 671-678.
37. Malagari K, Pomoni M, Kelekis A etal. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 2010; 33: 541-551.
38. Trojan J, Zeuzem S. To bead or not to bead: is transarterial chemoembolization with doxorubicin-eluting beads a new standard of care in hepatocellular carcinoma? Gastroenterology 2010; 139: 690-692.
39. Lencioni R, Malagari K, Vogl T etal. A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. J. Clin. Oncol.: ASCO Ann. Meet. Proc. 2009; 27: 207.
40. Burrel M, Reig M, Forner A etal. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J. Hepatol. 2012; 56: 1330-1335.